Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity.

Claudiu T Supuran

Expert opinion on emerging drugs 2012 Mar

filter terms:

Carbonic anhydrases (CAs, EC 4.2.1.1) are ubiquitous metalloenzymes in mammals, being involved in numerous biosynthetic processes, including gluconeogenesis, lipogenesis and ureagenesis. It has recently emerged that CA inhibitors (CAIs) targeting the mitochondrial isoforms CA VA and VB have potential as novel antiobesity drugs. This Editorial discusses the biochemical and biological rationale for the use of CAIs in the management of obesity.

Citation

Claudiu T Supuran. Carbonic anhydrase inhibitors as emerging drugs for the treatment of obesity. Expert opinion on emerging drugs. 2012 Mar;17(1):11-5